Asthma And COPD London, England, UK 11-12 April 2018

Description:
Recent advances in injectable biologics and smart medical devices as led to an increase in novel approaches to treating severe asthma and COPD as well as the regulations to take into consideration. As technology soars, the need for guideline updates from regulators has increased and continues to be modified.

With asthma and chronic obstructive pulmonary disorder (COPD) affecting about 500 million people worldwide, opportunities in drug development are vast and reducing serious attacks by improving adherence could save $19 billion a year in U.S. healthcare costs.

URL:
Booking: https://go.evvnt.com/173555-1

Speakers: Allergy Therapeutics, Amgen, AstraZeneca, Boehringer Ingelheim, Cambridge Consultants Ltd, GSK, Imperial College London, Janssen, Kings College London, MedImmune, MHRA, National Heart And Lung Institute, National University Health System, Singapore, NIHR Biomedical Research Centre, University of Edinburgh Medical School

Prices:
Book by 15th December and save £400: GBP 1099
Book by 31st January and save £200: GBP 1299
Book by 28th February and save £100: GBP 1399
Standard: GBP 1499

Time: 8:30 am to 5:30 pm